Diurnal Share Discussion Threads

[jpuff] 12/8/2022 10:05

I can hopefully see a bit of a recovery from here.

[bamboo2] 12/8/2022 09:49

This is from the original Eton Pharma press release 27 March 2020.
I understand delays have occurred because of Covid etc.
Surely we must be very close to the first trigger payment?
I have a small direct holding here. My main holding is in IPO group.
So apols in advance if I am behind the curve a bit.

=====================================================================

Eton believes the market opportunity for Alkindi Sprinkle in the United States is greater than $100 million annually.

Transaction Details

Upon execution of the agreement, Eton paid to Diurnal $3.5 million of cash and issued Diurnal 379,474 shares of Eton common stock, representing approximately $1.5 million based on Eton’s average fifteen-day trailing stock price. Upon commercial launch of the product with Orphan Drug Exclusivity granted, Eton will pay to Diurnal a cash milestone payment of $2.5 million.

Diurnal is entitled to commercial milestone payments upon Alkindi Sprinkle’s achievement of certain net sales thresholds, including:

$1 million when net sales exceed $10 million in a calendar year
$4 million when net sales exceed $25 million in a calendar year
$7.5 million when net sales exceed $50 million in a calendar year
$12.5 million when net sales exceed $100 million in a calendar year
$20 million when net sales exceed $200 million in a calendar year

In addition, Diurnal will receive a tiered royalty ranging from a low double-digit to high teens percentage on net sales of Alkindi Sprinkle.

[bamboo2] 12/8/2022 08:15

9.75 has become base support level over the past few weeks.
Todays potential breakaway gap up on the daily chart, should confirm at the end of the day.

[bad gateway] 12/8/2022 08:08

Market seems to like the news. Think myself the " feedback from the patient and physician communities continues to be overwhelmingly positive" comment bodes well for the rest of their territories.

[best1467] 12/8/2022 06:57

Yes have ETON on the Monitor

[bad gateway] 11/8/2022 21:41

Thanks best1467,appreciated.
They're very bullish on Alkindi going forward, foundation stone of their business by the looks of things.
Would recommend following the link below for full picture if interested in the stock.

Total Q2 2022 revenue of $7.4 million, up 139% from prior year
Recently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growth
Divestiture of hospital products division to focus on rare disease strategy
U.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamide oral suspension)
DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022.

“The second quarter of 2022 was a critical inflection point for the company. With the completion of the hospital products divestiture, we are now 100% focused on our rare disease strategy and are well capitalized to execute on our mission to be a leading rare disease company. Sales of our recently launched ALKINDI SPRINKLE® remain strong, with 293% year-over-year revenue growth, and feedback from the patient and physician communities continues to be overwhelmingly positive. Carglumic Acid also delivered another impressive quarter, with sales growing 100% sequentially. Physicians and patients appreciate the convenience of the room-temperature-stable product as well as the significant financial savings to the healthcare system compared to the competing product. We believe both products have long runways ahead of them and we are excited about the opportunities to add additional rare disease products to our portfolio this year,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals."


"Continued growth in ALKINDI SPRINKLE®. ALKINDI SPRINKLE sales grew 293% over the second quarter of 2021 and 34% over the first quarter of 2022, demonstrating a strong desire for the low-dose treatment options that ALKINDI SPRINKLE offers."

[best1467] 11/8/2022 17:04

ETON numbers out after the bell today

[small crow] 04/8/2022 16:06

That's a big trade.

[simon_64] 31/7/2022 12:05

I agree tb, but until they say how they are going to raise the required funds we will sadly be stuck here.

The one positive here though as their turnover increases they may be able to take out a loan rather than issue more shares.

[aimmafia] 28/7/2022 08:37

Tburns. Seeing as the share price is doing so well, I suspect the directors will be awarded more shares for current shareprice performance

[tburns] 27/7/2022 16:37

10p to buy now, the share is very unloved despite the +vd update

[simon_64] 26/7/2022 15:28

They have done a fantastic job against a very difficult climate.

I think the market is concerned with how are they are going to go about funding, as we know there are a number of ways they can do this without issuing further shares, but until they inform us of how much, how and when, we are not going to move much, but a steal at this price regardless. GLA.

[weatherman] 26/7/2022 12:44

The company should be given credit for meeting target - and will gain confidence, which will boost the price imo. Awaiting results and outlook.

[shirley83] 26/7/2022 12:16

High cash burn though, see this sub 10p

[deanmatlazin] 26/7/2022 08:29

The medication is the meds that they will take it FOR LIFE!

I can see the growth and recurring revenue in few years time. £16m in cash and revenue up to 100% to £4m. What a steal!

[genierub] 26/7/2022 08:25

...And finally investors realise how undervalued this really is. 68p year high and currently at 12p.

The buyers will just keep mounting. Once this breaks 15p, there's nothing stop this. Absolute gift if you read the numbers that were achieved in that RNS.

Its clear on Level 2 that even the MMs are not letting you take big chunks. Watch this move quickly when they let it go.

Tick Tock.

[best1467] 26/7/2022 08:10

Connect study

[best1467] 26/7/2022 08:04

Cash burn rate is likely to increase as the champagne trail builds momentum but if they can get through the next 12 months along with a positive data read then along with the Ditest potential I’m sure it’s looking positive long term.
Best case scenario would be some sort of upfront payment and royalty deal against future Ditest revenue which could be significant

[weatherman] 26/7/2022 07:50

They have advised previously they need more cash, but they have enough for 12 months, together with growing significant sales.

[bad gateway] 26/7/2022 07:38

Burnt through £8m in six months though so will need more growth in sales would have thought for a real turnaround?

[daveboy19] 26/7/2022 07:17

Hi Simon,
Better than I thought it would be. Hammering well overcooked as per usual. This is a very solid platform to build off.

[simon_64] 26/7/2022 07:09

Agreed dave the cash is almost as much as the MCAP.

[daveboy19] 26/7/2022 07:06

Very good update - might stop it going down today !!

[simon_64] 21/7/2022 06:32

Agrees weatherman maybe that is why we have not seen a bit of a rise after the director buys.

Market is looking for guidance to see if a fund raising is on the near horizon or someway off.

[weatherman] 19/7/2022 09:15

Should get an update before end of July.